

NIDA-Funded Publications

Book

Brandeau ML, Sainfort F, Pierskalla WP, eds. *Operations Research and Health Care: A Handbook of Methods and Applications*. Norwell, MA: Kluwer Academic Publishers; 2004.

Special Journal Issues

Brandeau ML, ed. *Interfaces - Special Issue on AIDS Modeling*. 1998.

Owens DK, ed. *Medical Decision Making - Special Supplement: Public Health Decision Making*. 2002.

Refereed Articles

Kahn JG. The cost-effectiveness of HIV prevention targeting: how much more bang for the buck? *Am J Public Health*. 1996;86(12):1709-1712.

Owens DK, Nease RF, Harris RA. Cost-effectiveness of human immunodeficiency virus (HIV) screening in acute-care settings. *Arch Intern Med*. 1996;156:394-404.

Parsonnet J, Harris RA, Hack HH, Owens DK. Modeling cost effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. *Lancet*. 1996;348:150-154.

Kahn JG, Gurvey J, Pollack LM, Binson D, Catania JA. How many HIV infections cross the bisexual bridge? *AIDS*. 1997;11:1031-1037.

Kahn JG, Sanstad KH. The role of cost-effectiveness analysis in assessing HIV prevention. *AIDS Public Policy J*. 1997;12:21-30.

Kaplan EH. Snapshot samples. *Socio-Econ Plann Sci*. 1997;31:281-291.

Owens DK, Cardinalli AB, Nease RF, Jr. Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. *Qual Life Res*. 1997;6:77-86.

Owens DK, Nease RF. A normative analytic framework for development of practice guidelines for specific clinical populations. *Med Decis Making*. 1997;17:409-426.

Owens DK, Shachter RD, Nease RF. Representation and analysis of medical decision problems with influence diagrams. *Med Decis Making*. 1997;17:241-262.

Paltiel AD, Kaplan EH. The cost-effectiveness of HIV screening: accounting for differential participation rates. *Med Decis Making*. 1997;17:490-495.

Scharfstein JA, Paltiel AD, Freedberg KA. The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. *Med Decis Making*. 1997;17:373-381.

Brandeau ML. AIDS policy modeling: a social role for operations research. *Ricerca Operativa*. 1998;27:5-33.

Caulkins JP, Kaplan EH, Lurie P, O'Connor T, Ahn S-H. Can difficult-to-reuse syringes reduce the spread of HIV among IDUs? *Interfaces*. 1998;28:23-33.

Dolan K, Wodak A, Hall W, Kaplan EH. A mathematical model of HIV transmission in New South Wales prisons. *Drug Alcohol Depend*. 1998;50:197-202.

Edwards DM, Shachter RD, Owens DK. A dynamic HIV-transmission model for evaluating the costs and benefits of vaccine programs. *Interfaces*. 1998;28:144-166.

Freedberg KA, Paltiel AD. Cost-effectiveness of prophylaxis for opportunistic infections in AIDS: an overview and methodologic discussion. *PharmacoEconomics*. 1998;14:165-174.

Freedberg KA, Scharfstein JA, Seage GR, 3rd, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. *J Amer Med Assoc*. 1998;279:130-136.

Kahn JG. Economic evaluation of primary HIV prevention in intravenous drug users. In: Holtgrave DR, ed. *Handbook of Economic Evaluation of HIV Prevention Programs*. New York: Plenum Press; 1998:45-62.

Kahn JG, Brandeau ML, Dunn-Mortimer J. Operations research modeling and AIDS policy: from theory to practice. *Interfaces*. 1998;28(3):3-22.

Kaplan EH. Economic evaluation and HIV prevention community planning - A policy analyst's perspective. In: Holtgrave DR, ed. *Handbook of Economic Evaluation of HIV Prevention Programs*. New York: Plenum Press; 1998:177-193.

Kaplan EH. To treat or not to treat? *Nature Med*. 1998;4:664-665.

- Kaplan EH, Pollack H. Allocating HIV prevention resources. *Socio-Econ Plann Sci*. 1998;32(4):257-263.
- Marseille EA, Kahn JG, Saba J. The cost-effectiveness of antiviral drug therapy to reduce mother-to-child transmission of HIV in sub-Saharan Africa. *AIDS*. 1998;12:939-948.
- Owens DK. Economic evaluations of HIV screening. In: Holtgrave DR, ed. *Handbook of Economic Evaluation of HIV Prevention Programs*. New York: Plenum Press; 1998:81-101.
- Owens DK. Interpretation of cost-effectiveness analyses. *J Gen Intern Med*. 1998;13:716-717.
- Owens DK, Brandeau ML, Sox CH. Effect of relapse to high-risk behavior on the costs and benefits of a program to screen women for human immunodeficiency virus. *Interfaces*. 1998;28(3):52-74.
- Owens DK, Edwards DE, Shachter RD. Population effects of preventive and therapeutic HIV vaccines in early- and late-stage epidemics. *AIDS*. 1998;12:1057-1066.
- Paltiel AD, Freedberg KA. The cost-effectiveness of preventing cytomegalovirus disease in AIDS patients. *Interfaces*. 1998;28:34-51.
- Paltiel AD, Scharfstein JA, Seage GR, et al. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. *Med Decis Making*. 1998;18 suppl:S93-S105.
- Paltiel AD, Stinnett AA. Resource allocation and the funding of HIV prevention. In: Holtgrave DR, ed. *Handbook of Economic Evaluation of HIV Prevention Programs*. New York: Plenum Press; 1998:135-152.
- Zaric GS, Brandeau ML, Bayoumi AM, Owens DK. The effect of protease inhibitors on the spread of HIV and the development of drug resistance: a simulation study. *Simulation*. 1998;71(4):262-275.
- Bluthenthal RN, Lorvick J, Kral AH, Erringer EA, Kahn JG. Collateral damage in the war on drugs: HIV risk behaviors among injection drug users. *Int J Drug Policy*. 1999;10:25-38.
- Kahn JG, Brindis CD, Gleit DA. Pregnancies and pregnancy consequences averted by the use of contraceptives in U.S. teens. *Fam Plann Perspect*. 1999;31:29-34.
- Kahn JG, Pinkerton SD, Paltiel AD. Postexposure prophylaxis following HIV exposure. *J Amer Med Assoc*. 1999;281:1269-1270.
- Kaplan EH, Brookmeyer R. Snapshot estimators of recent HIV incidence rates. *Oper Res*. 1999;47:29-37.
- Marseille EA, Kahn JG, Mmiro F, et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. *Lancet*. 1999;354:803-809.
- Richter A, Brandeau ML, Owens DK. An analysis of optimal resource allocation for HIV prevention among injection drug users and nonusers. *Med Decis Making*. 1999;19(2):167-179.
- Rupnow MF, Owens DK, Shachter R, Parsonnet J. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine methodology. *Helicobacter*. 1999;4:272-280.
- Scharfstein JA, Paltiel AD, Weinstein MC, et al. The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS. *Int J Technol Assess Health Care*. 1999;15:531-547.
- Elbeik T, Charlebois E, Nassos P, et al. Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5. *J Clin Microbiol*. 2000;38(3):1113-1120.
- Johri M, Kaplan EH. Treatment on demand: an operational model. *Health Care Manage Sci*. 2000;3:171-183.
- Kahn JG, Marseille E. Fighting global AIDS: the value of cost-effectiveness analysis. *AIDS*. 2000;14:2609-2610.
- Kaplan EH, Satten GA. Repeat screening for HIV: when to test and why. *J Acquir Immune Defic Syndr*. 2000;23:339-345.
- Paltiel AD. Remarks on the role of economic modeling. *Sex Transm Dis*. 2000;27:610-616.
- Troche CJ, Paltiel AD, Makuch R. Evaluation of therapeutic strategies: a new method of balancing risk and benefit. *Value Health*. 2000;3:12-22.
- Vold-Pepper P, Owens DK. Cost effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps. *Clin Infect Dis*. 2000;30:157-164.
- Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost effectiveness of methadone maintenance. *Am J Public Health*. 2000;90:1100-1111.
- Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. *J AIDS Hum Retrovirology*. 2000;25:403-416.
- Zaric GS, Brandeau ML, Barnett PG. Methadone maintenance treatment and HIV prevention: a cost effectiveness analysis. *Manage Sci*. 2000;25:1013-1031.

- Barnato AE, Sanders GD, Owens DK. Cost effectiveness of a potential vaccine for *Coccidioides immitis*. *Emerg Infect Dis*. 2001;7:797-806.
- Barnett PG, Zaric GS, Brandeau ML. The cost effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. *Addiction*. 2001;96:1267-1278.
- Brandeau ML. Difficult choices, urgent needs: optimal investment in HIV prevention programs. In: Kaplan EH, Brookmeyer R, eds. *Quantitative Evaluation of HIV Prevention Programs*. New Haven: Yale University Press; 2001:128-153.
- Freedberg KA, Losina E, Weinstein MC, et al. The cost-effectiveness of combination antiretroviral therapy for HIV disease. *New Engl J Med*. 2001;344(11):824-831.
- Heumann KS, Marx R, Lawrence SJ, et al. Cost-effectiveness of prevention referrals for high-risk HIV negatives in San Francisco. *AIDS Care*. 2001;13:637-642.
- Kahn JG, Haile B, Kates J, Chang S. The health and federal budgetary effects of expanding Medicaid to increase access to antiretroviral medications for HIV. *Am J Public Health*. 2001;91:1464-1473.
- Kahn JG, Kegeles SM, Hays R, Beltzer N. The cost-effectiveness of the Mpowerment Project, a community-level intervention for young gay men. *J Acquir Immune Defic Syndr*. 2001;27:482-491.
- Kahn JG, Marseille E, Saba J. Feeding strategies for children of HIV-infected mothers: modeling the trade-off between HIV infection and non-HIV mortality. In: Kaplan EH, Brookmeyer R, eds. *Quantitative Evaluation of HIV Prevention Programs*. New Haven: Yale University Press; 2001:249-271.
- Kaplan EH, Brookmeyer R, eds. *Quantitative Evaluation of HIV Prevention Programs*. New Haven, CT: Yale University Press; 2001.
- Marseille EA, Kahn JG, Billingham K, Saba J. Cost-effectiveness of the female condom in preventing HIV and STDs in commercial sex workers in rural South Africa. *Soc Sci Med*. 2001;52:135-148.
- Owens DK, Edwards DM, Shachter RD. Costs and benefits of imperfect HIV vaccines: implications for vaccine development and use. In: Kaplan EH, Brookmeyer R, eds. *Quantitative Evaluation of HIV Prevention Programs*. New Haven: Yale University Press; 2001:185-207.
- Paltiel AD. Model-based drug evaluation in chronic disease: promise, pitfalls, and positioning. *Drug Info J*. 2001;35:131-139.
- Paltiel AD, Goldie SJ, Losina E, et al. A pre-evaluation of clinical trial data: the case of pre-emptive CMV therapy in HIV. *Clin Infect Dis*. 2001;32:783-793.
- Rauner M, Brandeau ML. AIDS policy modeling for the 21st century: an overview of key issues. *Health Care Manage Sci*. 2001;4:165-180.
- Yazdanpanah Y, Chêne G, Losina E, et al. Incidence of primary opportunistic infections in two HIV-infected French clinical cohorts. *Int J Epidemiol*. 2001;30(4):864-871.
- Zaric GS, Brandeau ML. Optimal investment in a portfolio of HIV prevention programs. *Med Decis Making*. 2001;21:391-408.
- Zaric GS, Brandeau ML. Resource allocation for epidemic control over short time horizons. *Math Biosci*. 2001;171:33-58.
- Goldie SJ, Kaplan JE, Losina E, et al. Prophylaxis for HIV-related *Pneumocystis carinii* pneumonia (PCP): using simulation modeling to inform clinical guidelines. *Arch Intern Med*. 2002;162(8):921-928.
- Johri M, Paltiel AD, Goldie SJ, Freedberg KA. State AIDS Drug Assistance Programs (ADAPs): equity and efficiency in an era of rapidly changing treatment standards. *Med Care*. 2002;40(5):429-441.
- Kahn JG, Marseille E. A saga in international policy modeling: mother-to-child HIV transmission in the developing world. *J Policy Anal Manage*. 2002;21(3):499-505.
- Kahn JG, Zhang X, Cross LT, Palacio H, Birkhead GS, Morin S. Access to and use of HIV antiretroviral therapy: variation by race/ethnicity in two public insurance programs in the United States. *Public Health Rep*. 2002;117(3):252-262.
- Marseille EA, Hofmann PB, Kahn JG. HIV prevention before HAART in Sub-Saharan Africa. *Lancet*. 2002;359(9320):1851-1856.
- Morin SF, Sengupta S, Cozen M, et al. Responding to racial and ethnic disparities in use of HIV drugs: analysis of state policies. *Public Health Rep*. 2002;117(3):263-272.
- Owens DK. Analytic tools for public-health decision making. *Med Decis Making*. 2002;22(Suppl):S3-S10.
- Pinkerton SD, Kahn JG, Holtgrave DR. Cost-effectiveness of community-level approaches to HIV prevention: a review. *J Primary Prevention*. 2002;23:175-198.

- Zaric GS, Brandeau ML. Dynamic resource allocation for epidemic control in multiple populations. *IMA J Math Appl Med Biol.* 2002;19(4):235-255.
- Brandeau ML, Zaric GS, Richter A. Resource allocation for control of infectious diseases in multiple independent populations: beyond cost effectiveness analysis. *J Health Econ.* 2003;22:575-598.
- Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. *Am J Med.* 2003;115(8):632-641.
- Wilson A, Kahn J. Preventing HIV in injection drug users: choosing the best mix of interventions for the population. *J Urban Health.* 2003;80(3):465-481.
- Wilson A, Kahn J. Preventing HIV in injection drug users: exploring the tradeoffs between interventions. *Socio-Econ Plann Sci.* 2003;37(4):269-288.
- Zaric GS. Resource allocation for control of infectious disease epidemics. *Comments on Theoretical Biology.* 2003;8:475-496.
- Brandeau ML. Allocating resources to control infectious diseases. In: Brandeau ML, Sainfort F, Pierskalla WP, eds. *Operations Research and Health Care: Methods and Applications.* Norwell, MA: Kluwer Academic Publishers; 2004:443-464.
- Brandeau ML, Sainfort F, Pierskalla WP. Health care delivery: current problems and future challenges. In: Brandeau ML, Sainfort F, Pierskalla WP, eds. *Operations Research and Health Care: Methods and Applications.* Norwell, MA: Kluwer Academic Publishers; 2004:1-14.
- Marseille EA, Dandona L, Saba J, et al. Assessing the efficiency of HIV prevention around the world: methods of the PANCEA project. *Health Serv Res.* 2004;39:1993-2012.
- Owens DK, Edwards D, Cavallaro JF, Shachter R. The cost effectiveness of partially effective HIV vaccines. In: Brandeau ML, Sainfort F, Pierskalla WP, eds. *Operations Research and Health Care: Methods and Applications.* Norwell, MA: Kluwer Academic Publishers; 2004:403-418.
- Walensky RP, Paltiel AD, Goldie SJ, et al. A therapeutic HIV vaccine: how good is good enough? *Vaccine.* 2004;22(29-30):4044-4053.
- Zaric GS. Modeling the costs and effects of maintenance treatment for opiate addiction. In: Brandeau ML, Sainfort F, Pierskalla WP, eds. *Operations Research and Health Care: Methods and Applications.* Norwell, MA: Kluwer Academic Publishers; 2004:333-361.
- Brandeau ML. Modeling complex medical decision problems with the Archimedes model [Editorial]. *Ann Intern Med.* 2005;143(4):303-304.
- Brandeau ML, Zaric GS, de Angelis V. Improved allocation of HIV prevention resources: using information about prevention program production functions. *Health Care Manage Sci.* 2005;8:19-28.
- Dandona L, Sisodia P, Kumar SG, et al. HIV prevention programmes for female sex workers in Andhra Pradesh, India: outputs, cost and efficiency. *BMC Public Health.* 2005;5(Sep 24):98.
- Dandona L, Sisodia P, Prasad TLN, et al. Cost and efficiency of public sector sexually transmitted infection clinics in Andhra Pradesh, India. *BMC Health Serv Res.* 2005;5:69.
- Dandona L, Sisodia P, Ramesh YK, et al. Cost and efficiency of HIV voluntary counselling and testing centres in Andhra Pradesh, India. *Natl Med J India.* 2005;18(1):26-31.
- McConnel CE, Stanley N, Duplessis J-A, et al. The cost of a rapid test VCT clinic in South Africa. *S Afr Med J.* 2005;95:968-971.
- Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States: an analysis of cost effectiveness. *New Engl J Med.* 2005;352:586-595.
- Resch S, Altice FL, Paltiel AD. Cost-effectiveness of HIV screening for incarcerated pregnant women. *J AIDS.* 2005;38:163-173.
- Sanders GD, Bayoumi AM, Sundaram V, et al. Cost effectiveness of screening for HIV in the era of highly active antiretroviral therapy. *New Engl J Med.* 2005;352:570-585.
- Walensky RP, Weinstein MC, Kimmel AD, et al. Routine HIV testing: an economic evaluation of current guidelines. *Am J Med.* 2005;118:292-300.
- Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. *Med Decis Making.* 2005;25(3):321-329.
- Wilson AR, Kahn JG, Oren SS. Targeting interventions to high-risk populations: benefits and costs. *Socio-Econ Plann Sci.* 2005;39:335-349.

- Fuhlbrigge AL, Paltiel AD, Lee SJ, Kuntz KM, Weiss ST, CAMP Research Group. Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma. *Pediatrics*. 2006;118(2):e347-355.
- Honiden S, Sundaram V, Nease RF, et al. The effect of diagnosis with HIV infection on health-related quality of life. *Qual Life Res*. 2006;15(1):69-82.
- Kahn JG, Marseille EA, Auvert B. Cost-effectiveness of male circumcision for HIV prevention in a South African setting. *PLoS Med*. 2006;3(12):e517.
- Long EF, Brandeau ML, Galvin CM, et al. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. *AIDS*. 2006;20(17):2207-2215.
- Long EF, Brandeau ML, Galvin CM, et al. Оценка эффективности и экономической эффективности стратегии расширенной антиретровирусной терапии в Санкт-Петербурге, Россия. *AIDS* [2006; 2207-2215. Available at: <http://www.stanford.edu/dept/MSandE/cgi-bin/people/faculty/brandeau/brandeau.php>. Accessed Oct 31, 2011.
- Marseille E, Saba J, Musingo S, Kahn JG. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda. *AIDS*. 2006;20(6):907-914.
- Martin E, Pollack H, Paltiel A. Resource allocation in the Ryan White CARE Act: correlates of Title I and Title II Funding from 1998 to 2004. *Health Affairs*. 2006;25(1103-12).
- Paltiel AD, Walensky RP, Schackman BR, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. *Ann Intern Med*. 2006;145(11):797-806.
- Walensky RP, Paltiel AD. Rapid HIV testing at home: does it solve a problem or create one? *Ann Intern Med*. 2006;145:797-806.
- Walensky RP, Paltiel AD, Losina E, et al. Three million years of life saved: the survival benefits of AIDS treatment in the United States. *J Infect Dis*. 2006;194:11-19.
- Andersson KM, Owens DK, Vardas E, Gray GE, McIntyre JA, Paltiel AD. Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic: a South African example. *J AIDS*. 2007;46:78-90.
- Armbruster B, Brandeau ML. Contact tracing to control infectious disease: when enough is enough. *Health Care Manage Sci*. 2007;10:341-355.
- Armbruster B, Brandeau ML. Optimal mix of screening and contact tracing for endemic diseases. *Math Biosci*. 2007;10:386-402.
- Armbruster B, Brandeau ML. Who do you know? A simulation study of infectious disease control through contact tracing. *Proceedings of the 2007 Western Multiconference on Computer Simulation*. 2007:79-85.
- Lasry A, Zaric GS, Carter MW. Multi-level resource allocation for HIV prevention: a model for developing countries. *Eur J Oper Res*. 2007;180(2):786-799.
- Marseille EA, Dandona L, Marshall N, Kahn JG. HIV prevention costs and program scale: data from the PANCEA Project in five low- and middle-income countries. *BMC Health Serv Res*. 2007;7(Jul 12):108.
- McCormick AW, Walensky RP, Lipsitch M, et al. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. *Clin Infect Dis*. 2007;44(8):1115-1122.
- Owens DK, Sundaram V, Lazzeroni LC, et al. Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIV. *Am J Pub Health*. 2007;97(12):2173-2178.
- Owens DK, Sundaram V, Lazzeroni LC, et al. HIV testing and screening of at-risk patients in an integrated health care system. *J Gen Intern Med*. 2007;22(3):315-320.
- Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the United States. *Clin Infect Dis*. 2007;45(Suppl 4):S248-254.
- Zaric GS, Brandeau ML. A little planning goes a long way: multi-level allocation of HIV prevention resources. *Med Decis Making*. 2007;27(1):71-81.
- Auvert B, Marseille E, Korenromp EL, et al. Estimating the resources needed and savings anticipated from roll-out of adult male circumcision in Sub-Saharan Africa. *PLoS One*. 2008;3(8):e2679.
- Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection facility. *CMAJ*. 2008;179(11):1143-1151.

- Bendavid E. Monitoring of antiretroviral therapy in low-resource settings. *Lancet*. 2008;372(9635):288-289; author reply 289.
- Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, Owens DK. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. *Arch Intern Med*. 2008;168(17):1910-1918.
- Brandeau ML, Long EF, Hutton DW, Owens DK. Optimal spending on HIV prevention and treatment: a framework for evaluating the cost-effectiveness of HIV prevention and treatment programs with example application to The India AIDS Initiative. In: Lim GJ, Lee EK, eds. *Optimization in Medicine and Biology*. Boca Raton, FL: Taylor and Francis Publishers; 2008:147-175.
- Dandona L, Kumar SG, Ramesh YK, et al. Outputs, cost and efficiency of public sector centres for prevention of mother to child transmission of HIV in Andhra Pradesh, India. *BMC Health Serv Res*. 2008;8(Jan 31):26.
- Dandona L, Kumar SP, Ramesh Y, et al. Changing cost of HIV interventions in the context of scaling-up in India. *AIDS*. 2008;22 Suppl 1:S43-S49.
- Lasry A, Carter MW, Zaric GS. S4HARA: System for HIV/AIDS Resource Allocation. *Cost Eff Resour Alloc*. 2008;6:7.
- Long EF, Vaidya N, Brandeau ML. Controlling co-epidemics: analysis of HIV and tuberculosis infection dynamics. *Oper Res*. 2008;56(6):1366-1381.
- Potts M, Halperin DT, Kirby D, et al. Reassessing HIV prevention. *Science*. 2008;320(5877):749-750.
- Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Cost effectiveness of HIV screening in patients older than 55 years of age. *Ann Intern Med*. 2008;148(12):889-903.
- Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy (HAART). *Med Decis Making*. 2008;28:359-376.
- Bendavid E, Wood R, Katzenstein DA, Bayoumi AM, Owens DK. Expanding antiretroviral options in resource-limited settings – a cost-effectiveness analysis. *J AIDS*. 2009;52(1):106-113.
- Brandeau ML, Zaric GS. Optimal investment in HIV prevention programs: more is not always better. *Health Care Manage Sci*. 2009;12(1):27-37.
- Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic. *Ann Intern Med*. 2009;151(12):840-853.
- Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. *Ann Intern Med*. 2009;151(12):829-839.
- Long EF, Brandeau ML, Owens DK. Potential population health outcomes and expenditures of HIV vaccination strategies in the United States. *Vaccine*. 2009;27(39):5402-5410.
- Marseille EA, Kahn JG, Pitter CS, et al. The cost-effectiveness of home-based provision of antiretroviral therapy in rural Uganda. *Appl Health Econ Health Policy*. 2009;7(4):229-243.
- Paltiel AD, Freedberg KA, Scott C, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. *Clin Infect Dis*. 2009;48(6):806-815.
- Tole SP, Sanders GD, Bayoumi AM, et al. Cost-effectiveness of voluntary HIV screening in Russia. *Int J STD AIDS*. 2009;20(1):46-51.
- UNAIDS/WHO/SACEMA Expert Group on Modelling the Impact and Cost of Male Circumcision for HIV Prevention. Male circumcision for HIV prevention in high HIV prevalence settings: what can mathematical modelling contribute to informed decision making? *PLoS Med*. 2009;6(9):e1000109.
- Armbruster B, Brandeau ML. Cost-effective control of chronic viral diseases: finding the optimal level of screening and contact tracing. *Math Biosci*. 2010;34:35-42.
- Bendavid E, Brandeau ML, Wood R, Owens DK. Comparative effectiveness of HIV testing and treatment strategies in highly endemic regions. *Arch Intern Med*. 2010;170(15):1347-1354.
- Granich R, Crowley S, Vitoria M, et al. Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. *Curr Opin HIV AIDS*. 2010;5(4):298-304.
- Hutton DW, So SK, Brandeau ML. Cost effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. *Hepatology*. 2010;51:405-414.

- Long EF, Brandeau ML, Owens DK. The cost effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. *Ann Intern Med.* 2010;153(12):778-789.
- Martin EG, Paltiel AD, Walensky RP, Schackman BR. Expanded HIV screening in the US: what will it cost government discretionary and entitlement programs? A budget impact analysis. *Value Health.* 2010;13(8):893-902.
- Paltiel AD, Pollack HA. Price, performance, and the FDA approval process: the example of home HIV testing. *Med Decis Making.* 2010;30(2):217-223.
- Walensky RP, Wood R, Ciaranello AL, Paltiel AD, Lorenzana SB, et al. Scaling up the 2010 World Health Organization HIV treatment guidelines in resource-limited settings: a model-based analysis. *PLoS Med.* 2010;7(12):e1000382.
- Yadzanpanah Y, Sloan E, Charlois-Ou C, et al. Routine HIV screening in France: clinical impact and cost-effectiveness. *PLoS One.* 2010;5(10):e312132.
- Alistar SS, Brandeau ML. Decision making for HIV prevention and treatment scale up: bridging the gap between theory and practice. *Med Decis Making.* 2011;Epub ahead of print.
- Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. *PLoS Med.* 2011;8(3):e1000423.
- Alistar SS, Owens DK, Brandeau ML. Результативность и экономическая эффективность расширения программ снижения вреда и антиретровирусной терапии при «смешанной» эпидемии ВИЧ: анализ модели на примере Украины. *PLoS Med* [2011; e1000423. Available at: http://www.plosmedicine.org/attachments/pmed.1000423_Russian.pdf. Accessed Oct 31, 2011.
- Andersson KM, Owens DK, Paltiel AD. Scaling up circumcision programs in Southern Africa: the potential impact of gender disparities and changes in condom use behaviors on heterosexual HIV transmission. *AIDS Behav.* 2011;15(5):938-948.
- Andersson KM, Paltiel AD, Owens DK. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results. *Vaccine.* 2011;29(36):6107-6112.
- Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A. Effectiveness and cost-effectiveness of HIV antiretroviral regimens recommended in the World Health Organization's guidelines for resource-limited settings. *AIDS.* 2011;25(2):211-220.
- Enns EA, Brandeau ML. Inferring model parameters in network-based disease simulation. *Health Care Manage Sci.* 2011;14(2):174-188.
- Enns EA, Brandeau ML, Igame TK, Bendavid E. Assessing effectiveness and cost effectiveness of concurrency reduction for HIV prevention. *Int J STD AIDS.* 2011;22(10):558-567.
- Enns EA, Mounzer JJ, Brandeau ML. Optimal link removal for epidemic mitigation: a two-way partitioning approach. *Math Biosci.* 2011;Epub ahead of print.
- Hutton DW, So SK, Brandeau ML. Doing good with good OR: supporting cost-effective hepatitis B interventions. *Interfaces.* 2011;41(3):289-300.
- Juusola JL, Brandeau ML, Long EF, Owens DK, Bendavid E. The cost effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the United States. *AIDS.* 2011;25(14):1779-1787.
- Kahn JG, Granich R, Williams B, Bennett R. Review of cost-effectiveness issues in the expansion of anti-retroviral therapy. *Current HIV Research.* 2011;In press.
- Kahn JG, Harris B, Mermin J, et al. Cost of an integrated community prevention campaign for malaria, HIV, and diarrhea in rural Kenya. *BMC Health Serv Res.* 2011;11(1):346.
- Kahn JG, Marseille E, Moore D, et al. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. *BMJ.* 2011;343:d6884.
- Lasry AC, Malvankar MW, Zanic GS. Allocating funds for HIV/AIDS: the case of kwaDukuza, South Africa. *Health Policy Plann.* 2011;26(1):33-42.
- Long EF, Owens DK. The cost-effectiveness of a modestly effective HIV vaccine in the United States. *Vaccine.* 2011;29(36):6113-6124.
- Malvankar M, Zanic GS. Incentives for optimal allocation of HIV prevention resources in a multilevel model. *INFOR: Information Systems and Operational Research.* 2011;In press.

- Martin EG, Barry C. The adoption of mental health drugs on State AIDS Drug Assistance Program formularies. *Am J Public Health*. 2011;101(6):1103-1109.
- Martin EG, Keenan PS. Sticky dollars: inertia in the evolution of federal allocations for HIV care through the Ryan White Program. *Publius J Federalism*. 2011;41(1):101-125.
- Sloan CE, Champenois K, Choisy P, et al. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. *AIDS*. 2012;26(1):45-56.
- Alistar SS, Brandeau ML, Beck EJ. REACH (Resource Allocation for Control of HIV): a practical HIV resource allocation tool for decision makers. In: Zaric GS, ed. *Operations Research and Health Care Policy*. New York: Springer; In press.
- Brandeau ML. OR in public health: a little help can go a long way. In: Zaric GS, ed. *Operations Research and Health Care Policy*. New York: Springer; In press.
- Granich R, Kahn JG, Bennett R, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness, 2011-2050. *PLoS One*. In press.
- Kimmel AD, Daniels N, Betancourt TS, Wood R, Prosser LA. Decision maker priorities for providing antiretroviral therapy in HIV-infected South Africans: a qualitative assessment. *AIDS Care*. In press.
- Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of response guided therapy using protease inhibitors and IL-28B testing for chronic hepatitis C in the U.S. *Ann Intern Med*. In press.